• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对导管原位癌和匹配的相邻浸润性乳腺癌进行基因组和突变分析,揭示了肿瘤内遗传异质性和克隆选择。

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

机构信息

Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.

Department of Anatomic Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain.

出版信息

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

DOI:10.1002/path.3990
PMID:22252965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4975517/
Abstract

The mechanisms underlying the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) of the breast are yet to be fully elucidated. Several hypotheses have been put forward to explain the progression from DCIS to IDC, including the selection of a subpopulation of cancer cells with specific genetic aberrations, and the acquisition of new genetic aberrations or non-genetic mechanisms mediated by the tumour microenvironment. To determine whether synchronously diagnosed ipsilateral DCI and IDCs have modal populations with distinct repertoires of gene copy number aberrations and mutations in common oncogenes, matched frozen samples of DCIS and IDC were retrieved from 13 patients and subjected to microarray-based comparative genomic hybridization (aCGH) and Sequenom MassARRAY (Oncocarta v 1.0 panel). Fluorescence in situ hybridization and Sanger sequencing were employed to validate the aCGH and Sequenom findings, respectively. Although the genomic profiles of matched DCI and IDCs were similar, in three of 13 matched pairs amplification of distinct loci (ie 1q41, 2q24.2, 6q22.31, 7q11.21, 8q21.2 and 9p13.3) was either restricted to, or more prevalent in, the modal population of cancer cells of one of the components. Sequenom MassARRAY identified PIK3CA mutations restricted to the DCIS component in two cases, and in a third case the frequency of the PIK3CA mutant allele reduced from 49% in the DCIS to 25% in the IDC component. Despite the genomic similarities between synchronous DCIS and IDC, our data provide strong circumstantial evidence to suggest that in some cases the progression from DCIS to IDC is driven by the selection of non-modal clones that harbour a specific repertoire of genetic aberrations.

摘要

乳腺癌从导管原位癌(DCIS)进展为浸润性导管癌(IDC)的机制尚未完全阐明。已经提出了几种假说来解释从 DCIS 到 IDC 的进展,包括选择具有特定遗传异常的癌细胞亚群,以及通过肿瘤微环境获得新的遗传异常或非遗传机制。为了确定同时诊断的同侧 DCIS 和 IDC 是否具有模态群体,这些群体具有共同致癌基因中不同基因拷贝数异常和突变的特征,从 13 名患者中检索了 DCIS 和 IDC 的匹配冷冻样本,并进行了基于微阵列的比较基因组杂交(aCGH)和 Sequenom MassARRAY(Oncocarta v1.0 面板)。荧光原位杂交和 Sanger 测序分别用于验证 aCGH 和 Sequenom 的发现。尽管匹配的 DCIS 和 IDC 的基因组图谱相似,但在 13 对匹配的对中,有三个对中,不同部位(即 1q41、2q24.2、6q22.31、7q11.21、8q21.2 和 9p13.3)的扩增仅限于或更常见于其中一个成分的肿瘤细胞的模态群体中。Sequenom MassARRAY 在两种情况下鉴定了仅局限于 DCIS 成分的 PIK3CA 突变,在第三种情况下,PIK3CA 突变等位基因的频率从 DCIS 中的 49%降低到 IDC 成分中的 25%。尽管同步 DCIS 和 IDC 的基因组相似,但我们的数据提供了强有力的间接证据,表明在某些情况下,从 DCIS 到 IDC 的进展是由携带特定遗传异常谱的非模态克隆的选择驱动的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/92aaf7dbf5fb/emss-69401-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/d93980263a9e/emss-69401-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/03a4505271df/emss-69401-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/8be049f768cf/emss-69401-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/92aaf7dbf5fb/emss-69401-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/d93980263a9e/emss-69401-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/03a4505271df/emss-69401-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/8be049f768cf/emss-69401-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bc7/4975517/92aaf7dbf5fb/emss-69401-f004.jpg

相似文献

1
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.对导管原位癌和匹配的相邻浸润性乳腺癌进行基因组和突变分析,揭示了肿瘤内遗传异质性和克隆选择。
J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.
2
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma to Invasive Ductal Carcinoma.非低级别导管癌进展为浸润性导管癌的全外显子组测序分析。
Clin Cancer Res. 2020 Jul 15;26(14):3682-3693. doi: 10.1158/1078-0432.CCR-19-2563. Epub 2020 Mar 27.
3
Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.对导管原位癌和浸润性乳腺癌的单细胞遗传分析显示,尽管存在巨大的肿瘤异质性,但在进展过程中仍存在基因组失衡和 MYC 的获得。
Am J Pathol. 2012 Nov;181(5):1807-22. doi: 10.1016/j.ajpath.2012.07.012. Epub 2012 Oct 8.
4
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.通过荧光原位杂交和免疫组织化学检测纯导管原位癌以及浸润性导管癌的导管内和浸润成分中的HER2状态。
Histopathology. 2006 May;48(6):702-7. doi: 10.1111/j.1365-2559.2006.02403.x.
5
Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.广泛原位导管癌伴小灶浸润性导管癌:比较基因组杂交显示的基因相似性证据
Int J Cancer. 2000 Jan 1;85(1):82-6. doi: 10.1002/(sici)1097-0215(20000101)85:1<82::aid-ijc15>3.0.co;2-s.
6
Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.同步导管原位癌和浸润性乳腺癌中具有可比性的癌症相关突变特征。
Cancer Rep (Hoboken). 2020 Jun;3(3):e1248. doi: 10.1002/cnr2.1248. Epub 2020 May 28.
7
Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.肿瘤上皮和基质成分在乳腺癌进展过程中的基因表达谱分析。
Breast Cancer Res Treat. 2012 Aug;135(1):153-65. doi: 10.1007/s10549-012-2123-4. Epub 2012 Jun 21.
8
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.高级别导管原位癌中PI3K通路的激活——对进展为浸润性乳腺癌的意义
Clin Cancer Res. 2014 May 1;20(9):2326-37. doi: 10.1158/1078-0432.CCR-13-2267. Epub 2014 Mar 14.
9
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.PIK3CA 突变在导管原位癌和相邻浸润性乳腺癌中的作用。
Endocr Relat Cancer. 2019 May;26(5):471-482. doi: 10.1530/ERC-19-0019.
10
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.乳腺乳头状癌的免疫表型和基因组特征。
J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.

引用本文的文献

1
Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.浸润性导管癌及并存的导管原位癌中HER2表达的定量评估。
Breast Cancer Res Treat. 2025 Jul 18. doi: 10.1007/s10549-025-07781-9.
2
Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.纯导管原位癌的突变图谱及其与疾病预后和放疗反应的关联。
Breast Cancer Res. 2025 Jul 8;27(1):127. doi: 10.1186/s13058-025-02080-z.
3
DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges.

本文引用的文献

1
Gene expression profiling in breast cancer: classification, prognostication, and prediction.乳腺癌的基因表达谱分析:分类、预后和预测。
Lancet. 2011 Nov 19;378(9805):1812-23. doi: 10.1016/S0140-6736(11)61539-0.
2
The microenvironment in breast cancer progression: biology and implications for treatment.乳腺癌进展中的微环境:生物学及治疗意义。
Breast Cancer Res. 2011;13(6):227. doi: 10.1186/bcr2912. Epub 2011 Nov 1.
3
Immunophenotypic and genomic characterization of papillary carcinomas of the breast.乳腺乳头状癌的免疫表型和基因组特征。
导管原位癌进展与肿瘤微环境:分子见解与预后挑战
Cancers (Basel). 2025 Jun 10;17(12):1925. doi: 10.3390/cancers17121925.
4
Influence of Cancerization of Lobules in Ductal Carcinoma In Situ of the Breast on the Pathological Outcomes in Mastectomy Specimens.乳腺导管原位癌中小叶癌变对乳房切除术标本病理结果的影响。
Cancers (Basel). 2025 May 12;17(10):1634. doi: 10.3390/cancers17101634.
5
Identification of a Growth-Promoting Gene Cluster in the Region 2q24 as a Driver of Tumorigenesis in Childhood Hepatoblastoma.鉴定2q24区域中一个促进生长的基因簇作为儿童肝母细胞瘤肿瘤发生的驱动因素。
Am J Pathol. 2025 Aug;195(8):1553-1569. doi: 10.1016/j.ajpath.2025.04.006. Epub 2025 Apr 30.
6
The Microenvironment in DCIS and Its Role in Disease Progression.导管原位癌中的微环境及其在疾病进展中的作用。
Adv Exp Med Biol. 2025;1464:211-235. doi: 10.1007/978-3-031-70875-6_12.
7
Differential somatic coding variant landscapes between laser microdissected luminal epithelial cells from canine mammary invasive ductal solid carcinoma and comedocarcinoma.犬乳腺浸润性导管实性癌和粉刺癌的激光显微切割管腔上皮细胞之间的体细胞编码变异景观差异
BMC Cancer. 2024 Dec 18;24(1):1524. doi: 10.1186/s12885-024-13239-w.
8
Impact of surgical types on overall survival in patients with ductal carcinoma : an analysis based on the SEER database.手术类型对导管癌患者总生存期的影响:基于监测、流行病学和最终结果(SEER)数据库的分析
Gland Surg. 2024 Jun 30;13(6):910-926. doi: 10.21037/gs-23-468. Epub 2024 Jun 27.
9
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.从导管原位癌到浸润性乳腺癌的进展:分子特征及临床意义。
Signal Transduct Target Ther. 2024 Apr 3;9(1):83. doi: 10.1038/s41392-024-01779-3.
10
Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.同时性导管原位癌和浸润性乳腺癌的多组学分析。
Breast Cancer Res Treat. 2024 Jun;205(3):451-464. doi: 10.1007/s10549-024-07270-5. Epub 2024 Mar 24.
J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.
4
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.腺样囊性癌构成三阴性和基底样乳腺癌中基因组上不同的亚群。
J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.
5
Challenges translating breast cancer gene signatures into the clinic.将乳腺癌基因特征转化为临床应用所面临的挑战。
Nat Rev Clin Oncol. 2011 Aug 30;9(1):58-64. doi: 10.1038/nrclinonc.2011.125.
6
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.PIK3CA 突变很少表现出肿瘤内基因型异质性,并且在乳腺癌进展中被选择。
Breast Cancer Res Treat. 2011 Sep;129(2):635-43. doi: 10.1007/s10549-011-1601-4. Epub 2011 May 27.
7
Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study.导管原位癌与相邻浸润性乳腺癌的分子差异:多重连接依赖性探针扩增研究。
Cell Oncol (Dordr). 2011 Oct;34(5):475-82. doi: 10.1007/s13402-011-0043-7. Epub 2011 May 6.
8
Genetic interactions in cancer progression and treatment.癌症进展和治疗中的遗传相互作用。
Cell. 2011 Apr 1;145(1):30-8. doi: 10.1016/j.cell.2011.03.020.
9
Tumour evolution inferred by single-cell sequencing.单细胞测序推断肿瘤进化。
Nature. 2011 Apr 7;472(7341):90-4. doi: 10.1038/nature09807. Epub 2011 Mar 13.
10
Hallmarks of cancer: the next generation.癌症的特征:下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.